Should I buy or sell ProKidney stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PROK shares. View PROK analyst ratings or view top-rated stocks .

What is ProKidney's stock price target for 2024?

2 brokerages have issued 12-month target prices for ProKidney's shares. Their PROK share price targets range from $15.00 to $16.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 747.0% from the stock's current price. View analysts price targets for PROK or view top-rated stocks among Wall Street analysts .

How have PROK shares performed in 2023?

ProKidney's stock was trading at $6.86 at the beginning of 2023. Since then, PROK shares have decreased by 73.3% and is now trading at $1.83. View the best growth stocks for 2023 here .

When is ProKidney's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our PROK earnings forecast .

How were ProKidney's earnings last quarter?

ProKidney Corp. (NASDAQ:PROK) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02.

What ETF holds ProKidney's stock ?

ALPS Medical Breakthroughs ETF holds 177,981 shares of PROK stock, representing 1.93% of its portfolio.

Who are ProKidney's major shareholders?

ProKidney's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Social Capital Group LLC (4.92%), Morgan Stanley (4.37%), Northern Trust Corp (0.16%), Charles Schwab Investment Management Inc. (0.11%), Bank of New York Mellon Corp (0.05%) and Rhumbline Advisers (0.03%). View institutional ownership trends .

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ProKidney Stock Price, News & Analysis (NASDAQ:PROK)

$1.83

+0.02 (+1.05%)

(As of 02:42 PM ET)

Compare

Today's Range: $1.71
▼
$1.89
50-Day Range: $1.21
▼
$4.76
52-Week Range: $1.12
▼
$14.19

Volume: 284,402 shs
Average Volume: 460,843 shs
Market Capitalization: $430.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.50

ProKidney MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 747.0% Upside
$15.50 Price Target
Short Interest: Bearish
26.65% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$23.38 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.66) to ($0.76) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

828th out of 960 stocks

Biological Products, Except Diagnostic Industry

118th out of 135 stocks

3.5

Analyst's Opinion

Consensus Rating
ProKidney has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.50, ProKidney has a forecasted upside of 747.0% from its current price of $1.83.
Amount of Analyst Coverage
ProKidney has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
26.65% of the float of ProKidney has been sold short.
Short Interest Ratio / Days to Cover
ProKidney has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
Change versus previous month
Short interest in ProKidney has recently increased by 6.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ProKidney does not currently pay a dividend.
Dividend Growth
ProKidney does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PROK.

0.0

News and Social Media Coverage

Search Interest
Only 2 people have searched for PROK on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,379,021.00 in company stock.
Percentage Held by Insiders
44.99% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 16.94% of the stock of ProKidney is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for ProKidney are expected to decrease in the coming year, from ($0.66) to ($0.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ProKidney is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ProKidney is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About ProKidney Stock (NASDAQ:PROK)

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

PROK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PROK Stock News Headlines

November 30, 2023 | bizjournals.com

ProKidney makes two changes to C-suite, terminating long-serving COO and promoting from within for chief business officer

November 30, 2023 | finance.yahoo.com

ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer

December 8, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 21, 2023 | msn.com

ProKidney former 10% owner Chamath Palihapitiya discloses sale of over 7M shares

November 21, 2023 | finance.yahoo.com

ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference

November 17, 2023 | finance.yahoo.com

ProKidney Corp. (NASDAQ:PROK) Q3 2023 Earnings Call Transcript

November 17, 2023 | finance.yahoo.com

Companies Like ProKidney (NASDAQ:PROK) Are In A Position To Invest In Growth

November 16, 2023 | finance.yahoo.com

After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)

December 8, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

November 16, 2023 | markets.businessinsider.com

ProKidney’s Future Promising: REACT Trial Success and Strategic Enrollment Shift Boosts Buy Rating

November 15, 2023 | msn.com

ProKidney pauses manufacturing after audit, company says

November 14, 2023 | msn.com

ProKidney GAAP EPS of -$0.18

November 14, 2023 | finance.yahoo.com

ProKidney Reports Third Quarter Financial Results

November 14, 2023 | finance.yahoo.com

ProKidney Corp (PROK) Reports Q3 Financial Results: Focus on Chronic Kidney Disease Trials

November 13, 2023 | finance.yahoo.com

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

November 1, 2023 | benzinga.com

10% Owner At This Health Care Company Sells $645K of Stock

October 30, 2023 | finance.yahoo.com

ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023

October 23, 2023 | bizjournals.com

Power Player 2023: Tim Bertram, ProKidney

October 20, 2023 | benzinga.com

ProKidney 10% Owner Sold $1.21M In Company Stock

October 17, 2023 | finance.yahoo.com

ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

October 16, 2023 | investorplace.com

Is Chamath Palihapitiya Giving Up on ProKidney (PROK) Stock?

October 16, 2023 | msn.com

Prokidney says Palihapitiya Chamath sells ~486.9K shares

October 12, 2023 | finance.yahoo.com

Why Shares of ProKidney Were Dropping Thursday

September 22, 2023 | benzinga.com

ProKidney 10% Owner Trades $9.30M In Company Stock

September 13, 2023 | seekingalpha.com

REACT Or Retreat: ProKidney's Phase 3 Focal Point

September 6, 2023 | finance.yahoo.com

ProKidney confirms it will expand HQ complex, add 50 jobs in Winston-Salem

September 5, 2023 | finance.yahoo.com

ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference

See More Headlines

Receive PROK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PROK
CUSIP: N/A
CIK: 1850270
Web: www.prokidney.com
Phone: 336-999-7028
Fax: N/A
Employees: 87
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.50
High Stock Price Target: $16.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +756.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,030,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -7.44%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.36
Quick Ratio: 19.37

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($42.77) per share
Price / Book: -0.04

Miscellaneous

Outstanding Shares: 235,435,000
Free Float: 129,513,000
Market Cap: $426.14 million
Optionable: Not Optionable
Beta: 0.81

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Deepak Jain Ph.D. (Age 69)
Chief Operating Officer
Comp: $768.65k
Mr. Todd C. Girolamo Esq. (Age 58)
J.D., M.B.A., Chief Legal Officer & Corporate Secretary
Comp: $600.17k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PROK Stock Analysis - Frequently Asked Questions

Should I buy or sell ProKidney stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PROK shares.
View PROK analyst ratings or view top-rated stocks.
What is ProKidney's stock price target for 2024?: 2 brokerages have issued 12-month target prices for ProKidney's shares. Their PROK share price targets range from $15.00 to $16.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 747.0% from the stock's current price.
View analysts price targets for PROK or view top-rated stocks among Wall Street analysts.
How have PROK shares performed in 2023?: ProKidney's stock was trading at $6.86 at the beginning of 2023. Since then, PROK shares have decreased by 73.3% and is now trading at $1.83.
View the best growth stocks for 2023 here.
When is ProKidney's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our PROK earnings forecast.

How were ProKidney's earnings last quarter?: ProKidney Corp. (NASDAQ:PROK) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02.
What ETF holds ProKidney's stock ?: ALPS Medical Breakthroughs ETF holds 177,981 shares of PROK stock, representing 1.93% of its portfolio.
Who are ProKidney's major shareholders?: ProKidney's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Social Capital Group LLC (4.92%), Morgan Stanley (4.37%), Northern Trust Corp (0.16%), Charles Schwab Investment Management Inc. (0.11%), Bank of New York Mellon Corp (0.05%) and Rhumbline Advisers (0.03%).
View institutional ownership trends.
How do I buy shares of ProKidney?: Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PROK) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial